Presented at the 4th Microbiome R&D and Business Collaboration Forum: USA. To find out more, visit: www.global-engage.com Greg Kuehn, President and COO of Metabiomics, presents the MB-01 colorectal adenoma clinical research study, sequencing technology and microbiome diagnostics platform.

1. Metabiomics Safe Harbor Statement: This slide deck contains forward-looking
statements within the meaning of the Private Securities Litigation Reform Act of 1995,
including statements relating to the potential results and future outcomes our clinical
research and business plan; ability to discover biomarkers and diagnostic tests.
including the ability of the company’s tests to impact clinical practice. Forward-looking
statements are subject to risks and uncertainties that could cause actual results to
differ materially, and reported results should not be considered as an indication of
future performance. These risks and uncertainties include, but are not limited to: the
results of clinical and developmental studies and any resulting products and services;
the regulation of our tests by the FDA and other agencies abroad; and the other risks
set forth in the company’s business plans and presentations. These forward- looking
statements speak only as of the date hereof. Metabiomics disclaims any obligation to
update these forward-looking statements.
Microbiome MDx
Platform Overview
1

2. mission and vision
2Confidential and Proprietary Information - Not For Distribution
Our vision is to continuously advance our patented MultiTag™ DNA sequencing technology and metagenomics discovery platform to pursue
innovative molecular systems biology, biomarker discovery, and clinical research aimed at developing diagnostics and therapeutics for the
prevention of colon cancer and other gastrointestinal cancerous, autoimmune, and infectious diseases.
Our mission is to
Eliminate Colon Cancer
Worldwide with a Low-CosT,
Easy-to-use, Non-Invasive,
Screening test
for precancerous adenomas

3. colon cancer is a major global killer
121k
China
23%
56k
North America
11%
31k
South America
6%
Europe
34%
More than 1.5 million people around the world are diagnosed
with colon cancer each year, more than 600k die.
Colon cancer is the 3rd-most common cancer in the
world, and causes the 2nd-most number of deaths.
122k
Asia
23%
CRC creates $14 Billion in healthcare costs in the US
annually.
187k
In the US, there are 137,000 new cases every year, 56,000
deaths. 3Confidential and Proprietary Information - Not For Distribution

4. but it shouldn’t beColon cancer is the most preventable, yet least prevented cancer
4
47%
of Americans do not adhere to
public health screening
guidelines
60% of Cancers are not detected
until later stages 3 and 4
14M Colonoscopies are performed
annually
3%
Since 1998 there has been a
3% annual decline in CRC
deaths due to the detection
and removal of adenomas

5. Early Detection Saves Lives
5Confidential and Proprietary Information - Not For Distribution
It can take 10 years for a
polyp to develop into
cancer
100% 10-year survival
rate with detection of
pre-cancer
Stage 1 cancer rapidly
advances to stage 4 in a
few years
Chances of survival fall
drastically in late stage
cancers
Healthcare costs for
patients with stage 4
cancer is $140k
0%
25%
50%
75%
100%
$0
$35,000
$70,000
$105,000
$140,000
Pre-Cancer Stage 1 Stage 2 Stage 3 Stage 4
CRC Management Costs Survival Rate

6. intercepting colon cancer is Possible
6Confidential and Proprietary Information - Not For Distribution
Metabiomics Microbiome MDx is only test with high
sensitivity to hyperplastic polyps and adenomas
hyperproliferation
hyperplastic polyps
adenomatous polyps
Severe dysplasia
precancerous polyp
adenocarcinoma
malignant
invasive cancer
malignant

7. existing non-invasive Tests Miss Pre-Cancerous Polyps
7Confidential and Proprietary Information - Not For Distribution
Non-Advanced Adenomas
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
FOBT-low
FOBT-high
FIT-Low
FIT-M
id
Fit-HighEXAS
<
5
m
m
EXAS
<
5-9
m
m
Specificity Sensitivity
FOBT and FIT tests
detect blood in fecal
samples
Many adenomas do not
bleed, FOBT and FIT
have low sensitivity
FOBT & FIT tests have
utility due to high
specificity and low cost
Exact Sciences adds
methylation/mutation
markers + FIT
Epi ProColon blood test
claims no sensitivity to
adenomas
Advanced Adenomas
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
FOBT-low
FOBT-high
FIT-Low
FIT-M
id
FIT-High
FIT-DeepC
EXAS
Stage I-IV Cancer
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
FOBT-lowFOBT-high
FIT-Low
FIT-M
id
Fit-High
FIT-DeepC
EXAS
EpiProColon
Colorectal Cancer Screening for Average-Risk North Americans: An Economic Evaluation, Cologuard Exec Summary

8. We Have A Solution
8
Highest Accuracy
Metabiomics MultiTagDx screening test can
detect the smallest precancerous adenomas
Earliest Detection
Microbiome disruption/dysbiosis provides the
earliest warning signs of polyps and
carcinogenesis
Non-Invasive and Easy-to-Use
Low-cost, easy-to-use, stool collection kits require
no stool contact and can be mailed to our
centralized testing facility
Cost-Effective
Leveraging Next-Generation DNA Sequencing (NGS)
and our patented MultiTag process will reduce cost to
less than $200 per test
A game-changing Pre-Cancerous Adenoma Screening Test for
Colon Cancer Prevention
After detection, colon polyps will be removed via a
follow-up colonoscopy and polypectomy
88% - 96%
Sensitivity
92% - 96%
Specificity
Adenoma (119) vs Healthy (112)
10-fold cross-validation test
pre-publication, subject to change

9. metabiomics Team
9Confidential and Proprietary Information - Not For Distribution
Visionary Entrepreneur and Inventor,
Systems Engineer, Data Scientist
Thomas J. Kuehn, PHD
Chairman and CEO
Co-founder, Business Dev, Marketing,
Finance, R&D Management
Gregory J. Kuehn, MBA
President and COO
Experienced Executive, Sales
Reimbursement for Healthcare
Products + Services
Chris Metz
Business Development and Sales
Co-Founder, Pioneering molecular
ecologist, inventor, Former Director of
Harvard Genome Laboratory
Patrick Gillevet, PHD
Chairman Science Advisory Board
CEO COO
VP AB
Tom Soriano - DOCRO Regulatory
Bob Thiel, PHD - DOCRO Statistics
Jim Linfield. JD - Cooley LLP
Erich Veitenheimer, JD PHD Cooley LLP
Lila Hope, JD PHD Cooley LLP
Sandy Sterrett, Jr. JD Rimon P.C.
Mark Hayman, JD PHD;
Se Jin Song PHD
Masi Sikaroodi, PHD
Bob Brown, PHD
Tiffany Weir, PHD
Paul DeRidder, MD, PHD
Advisors and Consultants
Leading Gastroenterology Practitioner,
Crohns and Colitis Fdn, Am. Soc.
Gastrointestinal Endoscopy
Louis Korman, MD
VP and Chief Medical Officer
Gastroenterology & Internal Medicine
National Board Crohn’s and Colitis Fdn,
President, APCR Clinical Research
Robert Hardi, MD
VP Clinical Research Director
Board Certified Pathologist, Anatomic,
clinical, cytopathology Founder of
Capital Digestive Care CAP /CLIA Lab
Jeff Baybick, MD
VP Pathology and Lab Operations
CMO
VP VP

10. MB-01
Colorectal Neoplasia Clinical studyMB-01 is the largest and most rigorous human microbiome diagnostics clinical study to date producing breakthrough protocols and predictive modeling
results.
10Confidential and Proprietary Information - Not For Distribution
Specific Aims
Determine the sensitivity and specificity for
detection of colorectal neoplasia based on 16S
rRNA microbiome analysis and clinical risk factors
Study Design
cross-sectional, observational, case-controlled
study, IRB Approved, ClinicalTrials.gov:
NCT02141945, 2 colonoscopy center sites in metro
DC area, Capital Digestive Care
Patient Population
260 patients undergoing CRC screening by
colonoscopy with collection of three samples per
patient including rectal swab, home stool sample
and biopsy
Classification and Metadata
Clinically relevant classes were defined by
gastroenterologists and pathologists including:
Hyper-plastic Polyp, Adenomas, Advanced
Adenoma, Age, Gender, BMI, Race, History of Polyps

11. microbiome diagnostics workflowMetabiomics is developing and end-to-end pipeline for microbiome diagnostics
11Confidential and Proprietary Information - Not For Distribution
02. Automated Sample Prep
Nucleic Acid Extraction
16S PCR
01. Sampling Kits
Patient and physician friendly
sampling kits, proper preservation
of samples
03. MultiTag Sequencing
Primer Kits
Patented 16S Library Preparation
kits enabling multiplexing of 96 -
384 samples/run (see MultiTag
Sequencing slide)
05. Computational
Diagnostics
Automated software algorithm for
diagnostics based on multivariate
statistics and machine learning
technology
Physician Report
1. Qualitative detection of colorectal
polyps and adenomas,
2. Qualitative detection and
classification of colorectal
hyperplastic polyps,
adenomatous polyps, and/or
advanced adenomas
04. NGS Sequencing
MiSeqDx, Ion Torrent PGM,
HiSeqDx (future)
MultiTagDx
Process
Sample-to-insight,
96X, 192X, 384x high-
throughput, multiplexing

12. Microbiome Sampling methods and kitsInnovative sampling standards and kits that can be used by the patient at home or by the physician during an examination
12Confidential and Proprietary Information - Not For Distribution
Puritan Hydraflock® Swabs Origin Sciences - OriCol
Use as rectal swab or home stool sampling direct from toilet paper
Patient and physician friendly
Validated by MB-01 study, 500+ samples with minimal PCR failures
No bowel preparation required
Biomarker-rich samples human and microbiome DNA, RNA, proteins, antibodies
Large sampling surface contact and volume
Significant reduction of stool contamination
Quantitative sample reproducibility
OriCol™ is an innovative device for the convenient and
effective sampling of mucocellular material that has
migrated along the entire colon to the rectum.
Advanced Puritan Hydraflock® swabs and RNA/DNA
preservative for transport at ambient temperatures,
Use as rectal swab or home stool sampling direct from
toilet paper to the swab with no stool contact

13. patented Tagged Fusion Primers
multitag SequencingAwarded in the US in 2013 (US Patent No, 8603749) and Europe (EP 2082063) in 2014,
awarded in Canada in 2016. Divisional “MultiTag Primer Kit” patents allowed in EU and
awarded in US in 2016. Priority date of 11/15/2006.
13Confidential and Proprietary Information - Not For Distribution
Simplifies Library Preparation
MTS supports pooling and sample handling for
multiplexing, managing and optimizing
throughput of NGS process.
04
Saves Time by Eliminating
Ligation Step
The elimination of the extra ligation step
saves 1-2 hours per run.
05
Provides Patent Protection &
FTO for MDx Assays
The Mayo vs. Prometheus decision limits
the ability to patent a correlation with a
measurement of a natural process.
06
Cost-Effective Sample Barcoding and
Multiplexing
3-piece Fusion Primer contains:
1) Patient/Sample Barcode - unique oligonucleotide
2) Target Primer - i.e. 16S variable regions
3) Sequencing Adapter for MiSeqDX, Ion Torrent PGM, ect…
01
Minimizes PCR Amplification Bias
A critical feature because the ligation of sample barcodes in 2-step
process has been proven to distort microbial community profiling
(relative abundance OTU tables)
02
Yields Accurate/Reproducible
Quantification of Relative Abundances
Essential for molecular diagnostics, MultiTag (barcoded fusion
primers) are the gold-standard in leading microbiome labs around
the world. Other primer designs have been shown to negatively
impact the reproducibility of microbiome studies.
03
Jones, MB, Library preparation methodology can influence genomic and functional predictions in human microbiome research, pnas (2015)
Binladen J, Gilbert MTP, Bollback JP, Panitz F, Bendixen C (2007) The Use of Coded PCR Primers Enables High-Throughput Sequencing of
Multiple Homolog Amplification Products by 454 Parallel Sequencing. PLoS ONE 2(2): e197. doi:10.1371/journal.pone.0000197
Sikaroodi 2015- Quality control in multi-tag pyrosequencing of microbial communities
MultiTag Sequencing Ecogenomics Analysis US Patent No 8,603,749 B2

14. Platform Independent Protocol for
MultiTag Next-Generation
sequenCing
14
Patented solution for sample multiplexing and barcoding with a fusion primer designed to minimize library
preparation, cost per sample/run, and PCR amplification bias while providing accurate quantification of amplicon
abundances.
Library Preparation with Fusion Primers
Involves the preparation of a DNA Library comprising a high-
throughput NGS adapter, a sample-specific barcode sequence and a
target primer sequence that are fused by PCR.
Pool Samples / Multiplex
Primer kits can include 96, 192, 384 or any number of unique
barcoded primers for multiplexing samples.
NGS Sequencing
Platform-independent primers can be customized for Illumina or
Life Technologies adapters or any sequencing-by-synthesis
instrument.
Data Processing and De-multiplexing
Sequences are assigned to samples during bioinformatics
processing using the sample-specific tags/barcodes.
Confidential and Proprietary Information - Not For Distribution
01
02
03
04 5’
5’3’
3’
Barcoded Amplicon flanked by NGS Sequencing Adapters
16S or 18S Amplicon flanked by linker sequences
+ MultiTag sequencing fusion primers
Gene TargetBarcodeNGS Adapter
3’
5’
5’
5’
PCR amplification with barcoded/tagged forward and reverse primers

15. microbiome diagnostics
18
The human gut microbiome provides the earliest
warning of precancerous colon polyps and
carcinogenesis.
Disruption/Dysbiosis of the microbiome has been
linked to inflammatory responses and metabolic
processing alterations
Chronic inflammation is known to be an important
feature in CRC progression, linked to oxidative DNA
damage
Bacterial mutagens can also damage genomic DNA
16S rRNA Microbial DNA sequencing platform
Metabiomics assays begin with microbial nucleic
acid extraction and next-generation sequencing
Sources: McAllister 2014, Dulal 2014, O’Keefe 2015, Arthur et al 2012,
Boleij 2012, Bongers et al 2014
01
02
03
04

16. Human Gut
Microbiome
health & disease
19
The microbiome co-evolved with the human host and is an
important player in human health and disease.
Nature Review - A microbial perspective of human developmental biology
Nature Review - Diet-microbiota interactions as moderators of human metabolism
The microbiome activates and regulates the immune system.
Nature Review - The microbiome and innate immunity
Nature Review - The microbiota in adaptive immune homeostasis and disease
Cancer J Author Manuscript - Microbiota and Immune Responses in Colon Cancer
The healthy microbiome is the first line of defense by fighting
off pathogenic bacteria.
Nature Review - Interactions between the microbiota and pathogenic bacteria
10 to 1
trillions of microbial cells vs
human cells, microbial cells
weighs ~3 pounds
100 to 1
1M+ microbial genes vs
23k human genes
Dysbiosis of the microbiome has been linked to a broad range
of human diseases.
Nature Review - Microbiome-wide association studies link dynamic microbial
consortia to disease

17. Microbiome MDX pipeline
20Confidential and Proprietary Information - Not For Distribution
Biomarker
Discovery
Clinical
Trials
Diagnostic
Modeling
Clinical
Validation
Service
Launch
MultiTag 16S rRNA Primer Kits
Microbiome Health Assays
Colorectal Adenoma LDT
IBD/IBS LDT
Colorectal Adenoma and
Carcinoma FDA Cleared IVDs
Microbiome Health, Metabolic
Disease, Obesity & Diabetes
Therapeutic and
Pharmabiomic Discovery
Our Microbiome NGS Diagnostics Platform and NGS Microbiome Sequencing Solutions supports a pipeline of MDx services

18. Contact UsMetabiomics currently has a “virtual office” but is planning on expanding in the Fitzsimmons Technology Park on the Anschutz medical
campus in Aurora, Colorado
Confidential and Proprietary Information - Not For Distribution
Email & Website
http://metabiomics.com
invest@metabiomics.com
Phone & Fax
Phone: 571-354-6171
Fax: 720-367-5071
Social Media
facebook
twitter @metabiomics